Standard BioTools completes SomaLogic acquisition; provides audited FY2022 and unaudited 9M2023 financials

STANDARD BIOTOOLS INC.

Acquisition closed Jan. 5, 2024; SomaLogic becomes wholly owned subsidiary of Standard BioTools.
SomaLogic FY2022 revenue $97.7M, net loss $109.2M; FY2021 revenue $81.6M, net loss $87.5M.
Pro forma unaudited combined financials filed for FY2022 and 9M2023 reflecting the acquisition.
SomaLogic had $421.8M cash and equivalents and $647.4M total assets at Dec. 31, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.